Waters Gains FDA Clearance for Faster Bloodstream Infection Diagnostics System

Event summary

  • Waters Corporation received FDA 510(k) clearance for the BD BACTEC FXI Culture System on June 3, 2026.
  • The system reduces mean time to detection by ~3 hours (~15%) compared to the prior-generation system.
  • The system features a 50% increase in vial loading capacity, with up to 960-vial per module capacity.
  • The system was previously CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR) and licensed by the Japan Pharmaceuticals and Medical Devices Agency (PMDA).

The big picture

Waters' FDA clearance for the BD BACTEC FXI Culture System positions the company to capitalize on the growing demand for faster and more accurate bloodstream infection diagnostics. The system's ability to reduce detection time by approximately three hours is critical in acute care settings, where each hour of delayed sepsis treatment increases mortality by 3.6% to 9.9%. This strategic advancement aligns with broader industry trends towards automated, high-throughput diagnostic solutions that improve patient outcomes and operational efficiency in microbiology laboratories.

What we're watching

Market Adoption
How quickly U.S. laboratories will adopt the BD BACTEC FXI Culture System given its faster detection capabilities and higher throughput.
Competitive Response
Whether competitors will accelerate their own diagnostic system advancements in response to this FDA clearance.
Regulatory Expansion
The pace at which Waters can secure additional regulatory approvals in other major markets.

Related topics

Diagnostics